|
Shaun Kirkpatrick has over twelve years experience managing venture investments and technology development programs in the fields of cancer, inflammation, metabolic disease and neurological disorders, and technology platforms related to biotherapeutics and antibodies. As President and Chief Executive Officer of Research Corporation Technologies in Tucson, Ariz., Kirkpatrick oversees RCT's BioVentures investments, technology development programs and special licensing programs in North America, Europe and Australia. Mr. Kirkpatrick is also a member of the operations board for the Critical Path Institute, an institute formed with the FDA, SRI International and the University of Arizona to accelerate the development of safe human therapeutics. Kirkpatrick received his master's degree in international economics and science/technology in international relations from Johns Hopkins University School of Advanced International Studies in Washington, D.C., and Bologna, Italy. He graduated summa cum laude from The University of Arizona in Tucson with a dual major in economics and biology. | 